Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Pathophysiological differences separating small vessel disease (SVD) from Alzheimer's disease (AD) may alter treatment approach.
Why it matters
In this small pilot study of 14 subjects, both small vessel disease and Alzheimer's disease showed reduced late capillary flow compared with controls, suggesting a shared blood-brain barrier problem. The study is preliminary and does not test any treatment.
-
BACKGROUNDTraffic-related air pollution (TRAP) is a risk factor for Alzheimer disease (AD), where unresolved brain inflammation has been linked to deficits in the levels of free lipid mediators that enable the resolution of inflammation.
Why it matters
In rats exposed to traffic-related air pollution and in human postmortem prefrontal cortex, lower levels of esterified proresolving lipid mediators were associated with inflammation, synaptic loss and impaired glucose metabolism, and with older age in people with Alzheimer's disease. This identifies a possible mechanism but does not test any treatment, cure or prevention.
-
Alzheimer's disease (AD) is characterized by deficits in cognition, behavior, and intellectual functioning, and Mild Cognitive Impairment (MCI) refers to individuals whose cognitive impairment deviates from what is expected for their age but does not significantly interfere with daily activities.
Why it matters
This study used Poincare and Entropy methods on EEG signals to classify people with Alzheimer's disease, mild cognitive impairment and healthy individuals. It is a diagnostic classification method and does not test any treatment, cure or prevention.
-
BackgroundAlzheimer's disease (AD) is the most prevalent neurodegenerative disorder characterized by cognitive deficit and pathological accumulation of amyloid-β (Aβ) and tau proteins.
Why it matters
This study created macaque models by infusing AAV-Tau and Aβ into brain regions, producing a cognitive deficit lasting at least 10 months with tau, pTau, NfL and Aβ changes. It is an animal model intended for drug development and does not itself treat, cure or prevent Alzheimer's disease in people.
-
The anti-amyloid monoclonal antibody lecanemab received the US accelerated approval for mild cognitive impairment or mild dementia stage of Alzheimer disease in January 2023, which was converted into traditional approval in June 2023.
Why it matters
This article discusses how safety data on lecanemab after approval should be collected and interpreted, noting that regulatory review in Europe is still ongoing. It stresses that real-life post-marketing studies are needed to clarify the drug's long-term safety and its place in treatment.
-
Dementia, especially Alzheimer’s disease, is increasing due to population ageing and is projected to nearly triple by 2050.
Why it matters
Using indoor and outdoor location data, this study classified wandering and apathetic behaviour in people with mild cognitive impairment and Alzheimer's disease, correctly classifying 42 of 46 cases. It is a monitoring and behaviour-classification method, not a treatment or cure.
-
Utilizing clinical data, the highest ROC AUC scores attained were 0.989, 0.927, and 0.907 for the identification of the CN, MCI, and dementia stages, respectively.
Why it matters
This study uses machine learning on blood gene expression and clinical data to identify Alzheimer's disease stages and flags several genes as associated with AD risk. It is a diagnostic and risk-association study only and does not test any treatment, cure or prevention.
-
Widespread delivery of AD‐modifying therapies will require a combination of strategies to communicate the value of detection and treatment to patients, integrate PCPs into the detection and diagnosis pathway, and address capacity disparities across the United States.
Why it matters
This simulation model estimated that letting primary care practitioners diagnose and evaluate patients for Alzheimer's therapies would most reduce wait times for specialists and increase the number treated. It also estimated average wait times could be three times longer in rural than urban areas.
-
Extensive understanding of a drug’s real‐world target population can inform generalizability of clinical trial results and highlight unaddressed risk.
Why it matters
This study characterized demographics, comorbidities, and co-medications in newly diagnosed US Alzheimer's disease patients using Medicare claims, finding most were aged 75 or older and female. It provides real-world population information that can inform how broadly clinical trial results apply, but does not test a treatment, cure, or prevention.
-
Pre-diagnosis of common dementia conditions such as Alzheimer’s disease (AD) in the initial stages is crucial to help in early intervention, treatment plan design, disease management, and for providing quicker healthcare access.
Why it matters
This study developed a classification algorithm using cognitive and demographic data that reached above 92% accuracy in distinguishing dementia stages. It is a computer-based assessment method and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Alzheimer Disease (AD) constitutes a major global healthcare problem.
Why it matters
This consensus statement notes that standard Alzheimer's pharmacotherapies offer only modest transient cognitive and behavioral benefits, and that aducanumab was the first disease-modifying agent approved. It states that concerns about aducanumab's efficacy and side effects led regulatory institutions worldwide to restrict its use.
-
Autoimmune encephalitis (AE) is a potentially treatable cause of rapidly progressive dementia that may mimic Creutzfeldt-Jakob disease (CJD).
Why it matters
This study compared Alzheimer's spinal fluid biomarkers in people with Creutzfeldt-Jakob disease and autoimmune encephalitis to see if they could tell the two conditions apart. It is a diagnostic study and does not test any treatment or cure.
-
Due to a triplication of the amyloid precursor protein (APP) gene on chromosome 21, most people with Down's Syndrome (DS) are at high risk of developing an Alzheimer type of dementia associated with Down's Syndrome (DS-AD).
Why it matters
This paper discusses the challenges of diagnosing Alzheimer-type dementia in people with Down syndrome using current classification systems, noting that DS-AD is not a specific entity in any of them. It concerns diagnosis, not treatment, cure or prevention.
-
We investigated the effect of using smartphone-based calendars (Google and Outlook Calendar) on prospective memory in Alzheimer's disease (AD). we recruited two groups of participants with mild AD.
Why it matters
In a small study of people with mild Alzheimer's disease, those who used smartphone calendar reminders missed fewer planned events than those who used paper calendars. This suggests smartphone tools may help with everyday memory, but it is a small study and does not treat or prevent the disease itself.
-
Thirty-four years ago, amyloid-β 1-42 peptide was identified in amyloid plaques from brain tissue obtained from patients with Alzheimer disease (AD) and Down syndrome.
Why it matters
This review describes the clinical utility of cerebrospinal fluid biomarkers for amyloid plaque burden and tau tangle pathology, along with measurement challenges and guidelines for their use. It discusses diagnostic methods and does not present a treatment or cure for Alzheimer's disease.
-
We suggest a one-step quantification method for amyloid PET via a deep learning model.
Why it matters
This study developed a deep learning model to quantify amyloid PET scans without MRI preprocessing, achieving high agreement with conventional methods. It is a technical imaging study and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Alzheimer disease (AD) is a neurodegenerative disorder characterized by extracellular β-amyloid (Aβ) deposition.
Why it matters
Plasma from Alzheimer disease patients showed delayed clot initiation and formation, and this was linked to cognitive ability and more pronounced in younger patients. The authors suggest therapies to correct this clotting phenotype might be beneficial, but this was a laboratory finding and no treatment was tested.
-
Hemostatic biomarkers were higher in Vascular group compared to Alzheimer group whereas there was no difference in inflammatory biomarkers.
Why it matters
This small pilot study found no significant difference in IL6 and CRP between Alzheimer's and vascular dementia groups, though fibrinogen and d dimer were higher in vascular subgroups. It is about distinguishing types of dementia for diagnosis and prognosis, not about treating, curing, or preventing Alzheimer's.
-
36/100
The authors of this mini-review list the key benefits (e.g., positive results of the reviewed randomized clinical trials studies for the improvement of cognitive decline in AD) and limitations (e.g., low awareness of benefits of TCM in Europe) of Chinese medicine therapy for the treatment of AD.
Why it matters
This mini-review of five randomized trials discusses Chinese medicine as a possible non-pharmacological option and notes positive results for improving cognitive decline in Alzheimer's disease. It also notes limitations such as low awareness of these benefits in Europe, and it states the disease cannot be cured yet.
-
Alzheimer's disease (AD) is a devastating neurodegenerative disorder that causes progressive cognitive decline.
-
Efforts to clinically diagnose cases having dementia with Lewy bodies (DLB) identify those with a characteristic clinical syndrome (probable DLB) at the expense of missing an equal, if not greater, number of cases who have atypical presentations thought to be associated with coexisting Alzheimer pathologies.
-
The term oligomeropathies defines the neurodegenerative disorders associated with protein misfolding, where small soluble aggregates (oligomers 4-200 KDa) are the cause of neuronal dysfunction and are responsible for spreading the pathology.
-
36/100
Although Alzheimer disease (AD) remains a clinical diagnosis, biomarkers are in use to support the diagnosis.
Why it matters
This study explored how cerebrospinal fluid amyloid, total tau and phospho tau biomarkers performed in a Norwegian memory clinic, with diagnoses made blind to the fluid results. It is about diagnostic test performance, not about treating, curing or preventing Alzheimer's disease.
-
For several years Amyloid-beta peptide (Aβ) has been considered the main pathogenetic factor of Alzheimer's disease (AD).
-
Receptor for advanced glycation end products (RAGE) is a receptor of the immunoglobulin super family that plays various important roles under physiological and pathological conditions.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Multiple gene variants linked to Alzheimer's-type clinical dementia via GWAS are also associated with non-Alzheimer's neuropathologic entities
- Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
- A change in sleep pattern may predict Alzheimer disease
- Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study
- CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and ApoE4
- Understanding the impact of sex and gender in Alzheimer's disease: A call to action
- Effect of lifestyle activities on Alzheimer disease biomarkers and cognition
- Mild premorbid intellectual impairment as a resilience factor in Down syndrome associated Alzheimer's disease
- Therapeutic anti-amyloid β antibodies cause neuronal disturbances
- Diagnosis of Alzheimer's Disease